Novartis strikes up to $2 billion deal for Excellergy

Anabelle Colaco
30 Mar 2026, 01:46 GMT+10

Swiss drugmaker Novartis has agreed to acquire California-based biotech firm Excellergy in a deal worth up to US$2 billion, marking its second major acquisition in recent weeks
The company said on March 27 that the agreement includes upfront and milestone payments that could total up to $2 billion
Novartis said the acquisition will strengthen its presence in immunology, particularly in treating food allergies

BASEL, Switzerland: Swiss drugmaker Novartis has agreed to acquire California-based biotech firm Excellergy in a deal worth up to US$2 billion, marking its second major acquisition in recent weeks.

The company said on March 27 that the agreement includes upfront and milestone payments that could total up to $2 billion. The deal is expected to close in the second half of 2026, subject to regulatory approvals and other customary conditions.

Novartis said the acquisition will strengthen its presence in immunology, particularly in treating food allergies.

Excellergy's lead drug candidate, Exl-111, is being developed to provide earlier relief from allergy symptoms, the company said.

The move follows another recent acquisition announcement by Novartis, which last week said it would buy a breast cancer drug candidate from U.S. biotech firm Synnovation Therapeutics for up to $3 billion.

The latest deal is part of a broader strategy to expand Novartis' pipeline through targeted acquisitions and investments in high-growth therapeutic areas.

In April last year, Novartis outlined plans to invest $23 billion in the United States over five years to build and expand research and manufacturing capabilities.

The company has since begun construction on research and development and manufacturing facilities across four U.S. states, including California. It has expanded its radioligand therapy operations in Indiana and New Jersey.

The Excellergy acquisition is expected to complement those efforts by adding new allergy-treatment capabilities to Novartis' portfolio.

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Bangladesh Sun.

More Information

Asia Sports

Section

"You need to ask Cricket Australia": Rahane on why Green didn't bowl against Mumbai Indians

Mumbai (Maharashtra) [India], March 30 (ANI): Kolkata Knight Riders (KKR) Captain Ajinkya Rahane addressed a question regarding Cameron...

With 8 gold and a silver from KITG 2026, Karnataka swimmer Manikanta sets sight on Asian Games qualification

Raipur (Chhattisgarh) [India], March 29 (ANI): For the past couple of days, Karnataka swimmer Manikanta must have felt like a model...

"Virat bhai's only instruction was to...": Padikkal on Kohli's advice during run-chase against SRH in IPL 2026 season opener

Bengaluru (Karnataka) [India], March 29 (ANI): Royal Challengers Bengaluru (RCB) batter Devdutt Padikkal expressed delight at the team's...

"Kohli looks for ways to improve himself": Steyn after RCB's win over SRH in IPL season opener

Bengaluru (Karnataka) [India], March 29 (ANI): Former South Africa pacer Dale Steyn said that Virat Kohli's mentality has undergone...

PM Modi praises India's T20 WC success; hails Anahat Singh, Gulveer Singh for global feats

New Delhi [India], March 29 (ANI): Prime Minister Narendra Modi on Sunday celebrated a landmark period for Indian sport, applauding...

PM Modi lauds J-K's maiden Ranji Trophy triumph, praises region's growing sporting culture

New Delhi [India], March 29 (ANI): Prime Minister Narendra Modi on Sunday hailed Jammu and Kashmir's emergence as a hub for sporting...

Business

Section